Recent advancements in the treatment of chronic myelogenous leukemia.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Annual Review of Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1146/ANNUREV.MED.53.082901.103853PMID 11818480
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• Chronic myeloid leukemia: current treatment options.

  2001cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

  2000cited by this paper
• Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

  2000cited by this paper
• Biological and clinical review of stromal tumors in the gastrointestinal tract.

  2000cited by this paper
• A proposed classification of mastocytosis incorporating molecular genetics.

  2000cited by this paper
• STI 571 inhibits the kinase activity of wild type and juxtamembrane C-kit mutants but not the exon 17 D816V mutation associated with mastocytosis

  2000cited by this paper
• Mini-allografts: ongoing trials in humans

  2000cited by this paper
• Commentary on and reprint of Rowley JD, A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining, in Nature (1973) 243:290–293

  2000cited by this paper
• Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

  2000cited by this paper
• Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

  2000cited by this paper
• The molecular biology of chronic myeloid leukemia.

  2000cited by this paper
• Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

  2000cited by this paper
• Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

  2000cited by this paper
• Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

  2000cited by this paper
• CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.

  2000cited by this paper
• The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.

  2000cited by this paper
• KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

  2000cited by this paper
• Chronic myeloid leukemia.

  1999cited by this paper
• An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

  1999cited by this paper
• Favorable therapeutic index of a p210BCR-ABL-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

  1999cited by this paper
• In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.

  1999cited by this paper
• Chronic Myelogenous Leukemia: Biology and Therapy

  1999cited by this paper
• Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure

  1999cited by this paper
• Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.

  1998cited by this paper
• Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

  1998cited by this paper
• A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

  1998cited by this paper
• Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation

  1998cited by this paper
• Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient.

  1998cited by this paper
• Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

  1998cited by this paper
• Familial gastrointestinal stromal tumours with germline mutation of the KIT gene

  1998cited by this paper
• Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

  1998cited by this paper
• Protein tyrosine kinases and cancer.

  1997cited by this paper
• CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.

  1997cited by this paper
• The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.

  1997cited by this paper
• Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.

  1997cited by this paper
• Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.

  1997cited by this paper
• Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

  1997cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper
• Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

  1995cited by this paper
• Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.

  1994cited by this paper
• Acute leukaemia in bcr/abl transgenic mice

  1990cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

  1990cited by this paper
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

  1990cited by this paper
• Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

  1988cited by this paper
• Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

  1985cited by this paper
• Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.

  1983cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper
• A minute chromosome in human chronic granulocytic leukemia

  1960cited by this paper

• Discovery and mechanistic insights of novel Piperlongumine analogs as potent Bcr-Abl kinase inhibitors.

  2026cites this paper
• Cell Signaling in Cancer

  2019cites this paper
• CANCER THERAPY

  2018cites this paper
• N-acetylaminogalactosyl-decorated biodegradable PLGA-TPGS copolymer nanoparticles containing emodin for the active targeting therapy of liver cancer

  2018cites this paper
• The growth of K562 human leukemia cells was inhibited by therapeutic neural stem cells in cellular and xenograft mouse models.

  2018cites this paper
• RESEARCHARTICLE Association of GSTM 1 , GSTT 1 and GSTP 1 Ile 105 Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients

  2017cites this paper
• GAPDH and Tumorigenesis

  2017cites this paper
• Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients

  2017cites this paper
• Glutathione-S-transferase P1 as a risk factor for Egyptian patients with chronic myeloid leukemia

  2016cites this paper
• Targeting eradication of chronic myeloid leukemia using chimeric oncolytic adenovirus to drive IL-24 expression.

  2015cites this paper
• Inhibition of human chronic myelogenous leukemia K562 cell growth following combination treatment with resveratrol and imatinib mesylate.

  2015cites this paper
• GSTP1 (Ile105Val) Gene Polymorphism: Risk and Treatment Response in Chronic Myeloid Leukemia

  2014cites this paper
• The multidrug resistance pumps are inhibited by silibinin and apoptosis induced in K562 and KCL22 leukemia cell lines.

  2014cites this paper
• The Effect of ImatinibMesylate for Newly Diagnosed Philadelphia Chromosome-Positive , Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients : The Experience of Côte d ’ Ivoire

  2014cites this paper
• Mathematical Modeling of Cyclic Cancer Treatments

  2014cites this paper
• Evolutionary Dynamics of Drug Resistant Mutants in Targeted Treatment of CML

  2014cites this paper
• GSTP 1 ( Ile 105 Val ) Gene Polymorphism : Risk and Treatment Response in Chronic Myeloid Leukemia

  2013cites this paper
• MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1

  2013cites this paper
• Investigation of GSTP1 (Ile105Val) Gene Polymorphism in Chronic Myeloid Leukaemia Patients

  2012cites this paper
• The Worst Drug Rule Revisited: Mathematical Modeling of Cyclic Cancer Treatments

  2011cites this paper
• MYC in Chronic Myeloid Leukemia: Induction of Aberrant DNA Synthesis and Association with Poor Response to Imatinib

  2011cites this paper
• Mathematical modeling of cyclic treatments of chronic myeloid leukemia.

  2011cites this paper
• The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire

  2010cites this paper
• Building Stochastic Models for Cancer Growth and Treatment

  2010cites this paper
• Combination of Two but Not Three Current Targeted Drugs Can Improve Therapy of Chronic Myeloid Leukemia

  2009cites this paper
• Use of oncolytic viruses for the eradication of drug-resistant cancer cells

  2009cites this paper
• Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.

  2009cites this paper
• Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.

  2008cites this paper
• alpha-Actinin interacts with rapsyn in agrin-stimulated AChR clustering

  2008cites this paper
• Effect of Cellular Quiescence on the Success of Targeted CML Therapy

  2007cites this paper
• N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.

  2007cites this paper
• Hematopoietic stem cell transplantation in Australia and New Zealand, 1992-2004.

  2007cites this paper
• The drug development crisis: efficiency and safety.

  2007cites this paper
• Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.

  2007cites this paper
• Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer.

  2007cites this paper
• Overcoming K 562 Dox resistance to STI 571 ( Gleevec ) by downregulation of Pgp expression using siRNAs Research Article

  2007cites this paper
• Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®) versus interferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia

  2007cites this paper
• Myeloproliferative Disorders and Myelodysplastic Syndromes

  2007cites this paper
• Overcoming K562Dox resistance to STI571 (Gleevec) by downregulation of P-gp expression using siRNAs

  2007cites this paper
• Myeloproliferative Diseases: Molecular Genetics

  2006cites this paper
• Differenzierungs- und antiangiogene Therapie

  2006cites this paper
• Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase

  2006cites this paper
• Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias

  2006cites this paper
• Drug resistance in cancer: principles of emergence and prevention.

  2005cites this paper
• Tumor models for preclinical development of targeted agents.

  2005cites this paper
• Haemopoietic stem cell transplantation in Australia and New Zealand, 1992–2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry

  2005cites this paper
• Cytogenetic testing for therapeutic indication in cancer

  2005cites this paper
• Emergence and prevention of resistance against small molecule inhibitors.

  2005cites this paper
• Identification of TopBP1 as a c-Abl-interacting Protein and a Repressor for c-Abl Expression*

  2005cites this paper
• How and when should we monitor chimerism after allogeneic stem cell transplantation?

  2005cites this paper
• The impact of the completed human genome sequence on the development of novel therapeutics for human disease.

  2004cites this paper
• Chronic Myelogenous Leukemia—Molecular Diagnosis and Monitoring

  2004cites this paper
• Suppression of bcr‐abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study)

  2004cites this paper
• Imatinib mesylate‐sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases

  2004cites this paper
• C-myc expression in cell lines derived from chronic myeloid leukemia.

  2004cites this paper
• Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignancies.

  2004cites this paper
• Treatment Patterns, Outcomes and Costs Among Elderly Patients with Chronic Myeloid Leukaemia

  2004cites this paper
• Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells.

  2004cites this paper
• Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1

  2004cites this paper
• Inhibition of bcr‐abl and/or c‐abl gene expression by small interfering, double‐stranded RNAs

  2004cites this paper
• Antisense inhibition of Bcr‐Abl/c‐Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells1

  2004cites this paper
• High Affinity Molecules Disrupting GRB2 Protein Complexes as a Therapeutic Strategy for Chronic Myelogenous Leukaemia

  2003influential citation
• The RAS signal transduction pathway and its role in radiation sensitivity

  2003cites this paper
• Apoptosis and Cancer

  2003cites this paper
• Mutations of c‐kit at exons 17/13 are rare but clinically relevant in human subjects

  2003cites this paper
• Vogt‐Koyanagi‐Harada disease associated with interferon alpha‐2b/ribavirin combination therapy

  2003cites this paper
• Postsynaptic requirement for Abl kinases in assembly of the neuromuscular junction

  2003cites this paper
• Imatinib induces mitochondria‐dependent apoptosis of the Bcr‐Abl‐positive K562 cell line and its differentiation toward the erythroid lineage 1

  2003cites this paper
• Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update

  2003cites this paper
• SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.

  2003cites this paper
• Expression of c‐ABL, c‐KIT, and platelet‐derived growth factor receptor‐β in ovarian serous carcinoma and normal ovarian surface epithelium

  2003cites this paper
• Chronic myelogenous leukemia

  2003cites this paper
• The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

  2002influential citation
• Chromosome‐mediated alterations of the MYC gene in human cancer

  2002cites this paper
• Chronic myeloid leukemia mimicking idiopathic intracranial hypertension

  2001cites this paper